Variations on the hub-and-spoke model have blossomed in the drug development industry over the past few years — and a new antibody hub is entering the fray.
Protuoso Biosciences co-founders Willie Xiang (left) and Tim Lu
May 26, 2026 09:17 AM EDT
FinancingStartups
Exclusive: Protuoso gets $9.5M to build the next hub-and-spoke antibody developer
Kyle LaHucik
California startup Protuoso raises $9.5m for “mix-and-match” drug platform - Pharmaceutical Technology
Biohub unveils AI world model for drug discovery, enhancing protein design
Pfizer, Innovent strike $10B cancer drug deal
Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
Mark Zuckerberg's philanthropic venture unveils AI world model for drug discovery - The Economic Times
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
The US biotech’s technology integrates multiple protein modalities to simultaneously target a variety of disease mechanisms.
Fapon Biopharma and MOTE Therapeutics to Present Dual-Platform B-Cell Immunotherapy Franchise at BIO 2026
Waypoint Bio Raises $20M Series A Led by Amplify Partners to Advance AI-Designed Cell Therapies Toward the Clinic
Biohub releases open-source AI protein suite covering 6.8 billion proteins, backed by $500M in funding, to accelerate drug…
Expanding platform with next-generation VHH, lambda common light chain, and specialized long-CDR3 technologies MOUNTAIN VIEW, CA…
Things are happening fast at BridgeBio as it plugs away at the launch of blockbuster-in-waiting Attruby and prepares to…
